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Human Immunodeficiency Virus Type 1 (HIV-1) protease inhibitors (PIs) are the most potent class of drugs in
antiretroviral therapies. However, viral drug resistance to PIs could emerge rapidly thus reducing the effectiveness of
those drugs. Of note, all current FDA-approved PIs are competitive inhibitors, i.e., inhibitors that compete with
substrates for the active enzymatic site. This common inhibitory approach increases the likelihood of developing
drug resistant HIV-1 strains that are resistant to many or all current PIs. Hence, new PIs that move away from the
current target of the active enzymatic site are needed. Specifically, allosteric inhibitors, inhibitors that prohibit PR
enzymatic activities through non-competitive binding to PR, should be sought. Another common feature of current
PIs is they were all developed based on the structure-based design. Drugs derived from a structure-based strategy
may generate target specific and potent inhibitors. However, this type of drug design can only target one site at a
time and drugs discovered by this method are often associated with strong side effects such as cellular toxicity,
limiting its number of target choices, efficacy, and applicability. In contrast, a cell-based system may provide a
useful alternative strategy that can overcome many of the inherited shortcomings associated with structure-based
drug designs. For example, allosteric PIs can be sought using a cell-based system without considering the site or
mechanism of inhibition. In addition, a cell-based system can eliminate those PIs that have strong cytotoxic effect.
Most importantly, a simple, economical, and easy-to-maintained eukaryotic cellular system such as yeast will allow
us to search for potential PIs in a large-scaled high throughput screening (HTS) system, thus increasing the chances
of success. Based on our many years of experience in using fission yeast as a model system to study HIV-1 Vpr, we
propose the use of fission yeast as a possible surrogate system to study the effects of HIV-1 protease on cellular
functions and to explore its utility as a HTS system to search for new PIs to battle HIV-1 resistant strains.
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Cell-based high-throughput screeningIntroduction
HIV/AIDS is one of the most devastating diseases in the
world with approximately 34 million people living with
HIV in 2010 and approximately 2.7 million new infections
in the same year [1]. Use of antiretroviral therapy (ART)
can successfully reduce Human Immunodeficiency Virus
Type 1 (HIV-1) viral replication, of which HIV-1 protease
(PR) inhibitors (PIs) are the most potent viral inhibitors.* Correspondence: rzhao@som.umaryland.edu
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reproduction in any medium, provided the orHowever, one of the major challenges in using ART is the
emergence of viral drug resistance due to mutations in the
PR gene. Resistant mutations that accumulated during mul-
tiple ARTs may lead to cross drug resistance to most or all
PIs [2-4], raising a possibility that multi-drug resistant
viruses may ultimately outgrow the number of PIs available.
Therefore, there is an urgent need to develop new PIs that
are active against those drug-resistant HIV-1 PRs (dr-PRs).
This review looks at the mechanisms in which HIV-1 PR
alters host cellular functions such as apoptosis in CD4+ T-
lymphocytes, why PIs are such potent drugs, and how a
eukaryotic cell-based high-throughput screening (HTS) sys-
tem using the fission yeast (Schizosaccharomyces pombe) asd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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process and prevent dr-PRs from developing.Life cycle of HIV-1
The life cycle of HIV-1 (Figure 1) comprises of the follow-
ing distinct stages: 1) adsorption and fusion, 2) reverse
transcription, 3) integration, 4) viral gene expression, 5)
virus assembly and maturation, and 6) budding. The
matured infections virion consists of two copies of genomic
RNA and functional viral proteins: reverse transcriptase
(RT), integrase (IN) and protease (PR). When the HIV −1
virion is uncoated into the targeted host cell such as
a CD4+ T-lymphocyte, RT catalyzes the conversion of one
copy of the genomic viral RNA into a double-stranded
viral DNA (dsDNA) [5]. IN catalyzes its integration into
the host chromosome to form a proviral DNA [5-8]. Using
the host cellular system, copies of HIV-1 genomic material
as well as shorter strands of messenger RNA (mRNA) are
created. The mRNA strands are used as blueprint to make
long chains of HIV-1 precursor proteins. The precursors
are then cut by HIV-1 PR into smaller active proteins and
assembled into mature virions. Following the assembly of
viral RNA strands and smaller active proteins into a new
viral particle, the virion buds from the host cell to infect
another cell [9,10].
During the virion assembly phase of HIV-1 replication,
HIV-1 PR performs a series of 12 cleavages on the Gag,
Gag-Pol and Nef polyprotein precursors [11-15]. These
cleavages proceed in a sequential and highly specific man-
ner to produce active viral enzymes (RT, PR and IN), viralFigure 1 Life cycle of the HIV-1. Life cycle of HIV-1 occurs in 6 major ste
Reverse Transcriptase, 3) integration of viral dsDNA into genomic DNA by I
precursor by HIV-1 PR and assembly of proteins into mature viral particle, astructural proteins (capsid and nucleocaspid), and other
viral factors essential for viral replication and infection
[11,14]. Despite the specificity and sequential manner
of these cleavages, the 12 proteolytic sites bear little
resemblance to each other. There is currently the real
substrate of HIV-1 PR and the factors governing substrate
recognition [11,12,16].HIV-1 protease
PR belongs to the family of aspartic proteases. The structure
of PR (Figure 2) is a homodimer and consists of subunits of
99 amino acid residues [5,9,17-22]. Each subunit is made up
of nine β-strands and a single α-helix. Four anti-parallel β-
strands form the highly stable dimer interface which consti-
tutes the active site [5,19,20,22,23]. The core of the active
site is hydrophobic and contains two aspartic acid residues
contributed by both subunits. Flexible anti-parallel β-sheets
from both monomers form two flaps that cover the active
site thereby restricting access to it [5,21,24-26]. In the free
enzyme state, the flaps assume a semi-open conformation
[21,22,27,28] and with a ligand in the active site, they as-
sume a closed conformation [5,22,26,29-31]. It has been
reported that, a network of weakly polar interactions be-
tween the flaps keeps them in a semi-open conformation
[21]. Two models have been used to explain the mechan-
isms of flap opening and closing. In the first model, the lig-
and forms a collision complex with HIV-1 PR in the open
flap conformation as it enters the active site of the PR and
then induces the flaps to close [32]. In the second model,
the ligand approaches the HIV-1 PR in the semi-open flapps: 1) adsorption and fusion of viral particle, 2) reverse transcription by
ntegrase, 4) expression of viral genes, 5) cleavage of Gag-pol and Gag
nd 6) budding of mature virion from host cell.
Figure 2 Structure of HIV-1 protease bound to TL-3, a
competitive protease inhibitor. Figure was obtained with
permission from [9].
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conformation as it enters the active site. The flaps then ex-
tend over the substrate and allow proteolysis to occur
[21,32,33]. The PR cleavage site on the Gag and Gag-Pol
precursor contain the unique amino acid sequences of Phe-
Pro and Tyr-Pro [5].
Effects of HIV-1 PR on host cellular functions
In addition to cleaving viral precursors, HIV-1 PR also
cleaves host cell proteins. There is growing evidence that
proteolysis and depletion of cellular proteins lead to
both necrotic cell death and apoptotic cell death of the
infected CD4+ T-cell. This can occur through several
pathways and contribute to the overall CD4+ T-cell de-
pletion in HIV/AIDS patients.
HIV-1 infection leads to necrotic/lytic cell death of the
infected CD4+ T-cell, resulting in CD4+ T-cell depletion,
a hallmark of HIV/AIDS [34,35]. However, the specific
mechanisms of CD4+ T-cell depletion is elusive. Re-
cently, CD4+ T-cell depletion has been directly asso-
ciated with the actions of HIV-1 PR. Blanco et al. found
that HIV-1 PR expression in COS7 monkey kidney cells
resulted to visual changes associated with cell necrosis
such as accumulation of cell debris, cellular swelling,
vacuolization, and loss of plasma membrane integrity
[36]. Treatment of HIV-1 PR expressing C8166 human
lymphocytes and COS7 cells with the protease inhibitor
Saquinavir inhibited these necrotic effects [36,37]. Fur-
thermore, removal of Saquinavir from PR-expressing
C8166 cells resulted to reactivation of HIV-1 PR and cel-
lular necrosis [37]. These results suggest that the nec-
rotic process is a direct result of the proteolysis of
cellular proteins by HIV-1 PR. The exact mechanism(s)
leading to necrotic cell death is currently unclear.
HIV-1 PR proteolysis of cytoskeletal proteins has been
linked to necrotic or apoptotic cell death. HIV-1 PR has
been shown in vitro to cleave many cytoskeletal proteins,including actin, desmin, myosin, tropomyosin, troponin C,
vimentin, alzheimer amyloid precursor protein, and glial fi-
brillary acidic protein [38-43]. Of these cytoskeletal proteins,
vimentin is a known substrate for HIV-1 PR in vivo. Injec-
tion of purified HIV-1 PR into human fibroblastic cells
resulted to in disruption of stress fibers, collapse of the cyto-
plasmic vimentin intermediate filaments, and changes in nu-
clear morphology and chromatin organization [43]. The
cytoplasmic structural changes are a direct result of cleavage
of cytoplasmic vimentin and other structural proteins by
HIV-1 PR [43]. Changes in nuclear morphology and chro-
matin organization are believed to be initiated by an N-
terminal fragment of cleaved vimentin [39]. When HIV-1
PR cleaves vimentin, it produces an N-terminal fragment
that, unlike uncleaved vimentin, is able to infiltrate the
nucleus and cause structural changes via a mechanism cur-
rently unclear [39]. These cellular effects are certainly detri-
mental and likely to be involved in either necrosis or
apoptosis. However, there is currently inadequate evidence
to support whether cleavage of these cytoskeletal proteins
triggers cell death and if so, how.
HIV-1 PR induces CD4+ T-cell apoptosis by decreasing
concentration of cellular protein Bcl-2 [44,45], an anti-
apoptotic member of the Bcl-2 protein family [46].
Strack et al. found that prior to apoptosis in several cell
lines induced to express HIV-1 PR, intact Bcl-2 was un-
detectable and fragmented Bcl-2 level was abnormally
high [44]. Further experiments showed that ectopic ex-
pression of bcl-2 in PR-expressing lymphocytes in vivo
and in vitro decreased apoptosis and suppressed HIV-1
PR activity, indicating that Bcl-2 protects cells from the
cytotoxic effects of HIV-1 PR and apoptosis [44]. Add-
itionally, cells expressing bcl-2 in vitro and in vivo
showed lower rates of apoptosis compared to cells that
did not, suggesting that Bcl-2 depletion is a requirement
for PR-induced apoptosis [44]. The loss of anti-apoptotic
function of the cleaved Bcl-2 is likely due to removal of
the BH3 and BH4 domain following cleavage between
residue 112 and 113 [44,47]. Normally, Bcl-2 inhibits
apoptosis by dimerizing with pro-apoptotic factors of the
Bcl-2 protein family. Both BH3 (ligand domain) and BH4
(cell death protecting domain) are essential for this func-
tion: BH3 is responsible for binding to BH3 containing
pro-apoptotic factors [48] and BH4 is responsible for
interacting with Raf kinases [47,49]. Hence, removal of
these domains will most likely result to a loss of Bcl-2
function, leading to apoptosis.
HIV-1 PR also induces apoptotic cell death via the prote-
olysis of Procaspase 8 between residue 355 and 356 to form
Casp8p41, a truncated form of Procaspase 8 that signals cell
death [50-52]. The exact mechanism by which Casp8p41
causes apoptosis has not been elucidated, but several key
players have been identified. First, cleavage of Procaspase 8
into Casp8p41 is essential for this apoptosis-inducing
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T-lymphocyte cell line producing cleavage-resistant Pro-
caspase 8, apoptosis is drastically reduced compared to
cells producing wild-type Procaspase 8 [52]. Second,
Casp8p41 acts through the intrinsic/mitochondrial apop-
totic pathway, a pathway in which internal stimuli induce
mitochondrial release of pro-apoptotic proteins to carry
out apoptosis. Casp8p41 localizes in the mitochondria, the
initiation site of the intrinsic apoptotic pathway [53]. In
addition, Casp8p41 pathway requires Caspase 9 and Bax/
Bak; casp8p41 transfection in cells with caspase 9 or bax/
bak knockout causes minimal cell death compared to
non-knockout cells [53]. Caspase 9 is an initiator caspase
of the intrinsic apoptotic pathway that activates Procas-
pase 3 into Caspase 3, the most important executioner
caspase [46]. Bax and Bak are both pro-apoptotic mem-
bers of the Bcl-2 protein family that govern mitochondrial
membrane permeability [46], which activates the intrinsic
apoptotic pathway with Bax and Bak being essential regu-
lators. Evidence suggests that the Casp8p41 pathway is a
major cause of cell death associated with HIV-1 PR.
Lymphoid tissues from HIV-1 infected patients showed
that cells with Casp8p41, experienced a drastically
increased rate of apoptosis and higher levels of pro-
apoptotic factor Caspase 3 compared to cells void of
Casp8p41 [50,52]. Furthermore, inhibition of HIV-1 PR
cleavage of Procaspase 8 into Casp8p41 in I.9.2 cells
(described above), resulted to in a large reduction of cell
death in cells transfected with HIV-1 PR [52].
It is clear that HIV-1 PR’s role is not limited to the
cleavage of viral precursor proteins and assembly of the
mature virions. HIV-1 PR cleaves an array of cellular
proteins and contributes to HIV-induced cytotoxicity
through several pathways.
Current state of HIV therapy
Currently, the gold standard of HIV treatment is highly
active antiretroviral therapy (HAART). HAART is a
cocktail of drugs from several classes of antiretroviral
drugs (ARVs), each of which inhibits one step of the
HIV-1 life cycle. For example, PIs prevent protease from
cleaving the Gag and Gag-Pol precursor polyproteins,
thus inhibiting the assembly and maturation of the viral
particle; RT inhibitors prevent conversion of viral gen-
omic RNA into viral DNA, thus stopping viral DNA in-
tegration into host chromosome. The multiple ARVs
present in HAART work together to suppress HIV-1 at
multiple stages of the viral life cycle. For many years,
HAART has been proven to effectively decrease viral
load and increase CD4+ T-cell count, thus improving the
quality of life of HIV/AIDS patients. Recent reports
show that a HIV-1 infected patient can expect to have a
close-to-normal life span if the virus is diagnosed early
and treated with adequate HAART [54,55].HIV-1 protease inhibitors
Of all the ARV drugs, PIs are the most potent because
they improve the clinical outcome of HIV patients in three
important ways. First, PIs suppress HIV-1 PR by prevent-
ing the assembly of mature virion, thus preventing viral
replication and decreasing viral load. Second, PIs inhibit
PR cleavage of host cell proteins (described above), which
reduces PR-related cytotoxicity, apoptosis, and necrosis in
infected host cells. Third, PIs have anti-apoptotic effects
via a mechanism not directly related to HIV-1 PR sup-
pression. This emerging area of research will not be dis-
cussed in this paper, but is extensively reviewed in [56,57].
These three major benefits of PIs make them essential to
any HAART.
Because PIs are so important to HAART, the develop-
ment of viral resistance to PIs may have dire public
health consequences. Currently, there are eleven FDA
approved PIs on the market [58]. These PIs all belong to
the same mechanistic class of competitive inhibitors:
inhibitors that bind to the active site of PR to prevent
substrate association [59,60]. One major problem with
this commonality among PIs is that PR mutations in the
active site may interfere with active site geometry and
lead to cross-resistance to multiple or all protease inhi-
bitors [2-4,61]. To combat this problem, we need to con-
sider potential alternative strategies such as developing
allosteric PIs, i.e., non-competitive inhibitors that inhibit
HIV-1 PR at a site other than the active site. The exist-
ing PR mutants resistant to the competitive PIs are less
likely to confer cross-resistance to the allosteric PIs be-
cause allosteric inhibitors do not compete with sub-
strates for the active site.
One class of promising allosteric inhibitor is the com-
pounds that interact with the flaps covering the HIV-1 PR
active site (Figure 2). Alteration of the flaps interferes with
substrate docking to reduce PR activity. Polyoxometalates
(POM) are a class of large inorganic flap-binding allosteric
inhibitors [62]. Although POMs are potent PIs, they were
initially found to be too toxic for clinical use [63]. Recent
research has been focused on modifying the functional
groups of POMs in a way that maintains its potency while
reducing its cytotoxicity [64]. A particularly promising
group of candidate PIs are the C3-substituted cyclopentyl-
tetrahydrofuranyl (Cp-THF) compounds, a recently
designed group of flap-binding small molecule inhibitors
[65,66]. Ghosh et al. found that several Cp-THFs effectively
inhibit a panel of dr-PRs in vitro, demonstrating their po-
tential to combat dr-PRs [65,66].
Another allosteric PI class being investigated are
dimerization inhibitors. Dimerization inhibitors inhibit
HIV-1 PR by binding to the dimerization interface and
preventing the formation of the active PR homodimer.
Bouras et al. first reported a dimerization inhibitor that
interfered with the β-sheet dimerization interface of the
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been developing a dimerization inhibitor design [68-72]
that cross-links the interfacial peptides of HIV-1 PR to
prevent formation of the active homodimer protein [71].
Significant progress has been made towards designing
allosteric inhibitors, but we currently have no FDA-
approved allosteric inhibitor. Like current FDA-approved
competitive inhibitors, all allosteric inhibitors in develop-
ment were discovered through a structure-based design.
In a structure-based design, inhibitors are selected, using
structural data or computational predictions, to fit a speci-
fied site on the target protein and assayed in vitro for
binding affinity. The inhibitors are then improved upon by
a trial-and-error process in which structural modifications
are made, assayed for binding affinity, and compared.
After the in vitro potency of the drug has been demon-
strated, the drug is then tested in vivo. There are several
limitations to this system. The structure-based method
requires extensive knowledge of the structure of the sub-
strate and inhibitor, limiting what it can screen for. Since a
structure-based design focuses on fitting an inhibitor to a
specific site on the protein (usually the active site), it can
only look for inhibitors to one site at a time. Finally, the
structural design may generate PIs that are target specific
and potent, but come with strong adverse effect such
as cellular toxicity, thus diminishing their efficacy and ap-
plicability.
Cell-based drug screenings and future perspectives
A cell-based system to screen for PIs holds several
advantages over a structure-based design. First, since a
cell-based system does not require structural knowledge
of the target protein, it is not restricted by the availabil-
ity of structural data of proteins such as dr-PRs with
conformational changes from the wild-type PR. Second,
allosteric PIs could be sought in a cell-based system
purely based on their inhibitory effect of HIV-1 PR-
induced cell death without considering the site of inhib-
ition. This is because a cell-based HTS looks at results
at the cellular level, allowing it to target the whole HIV-1
protease. What this means is that a cell-based system can
potentially identify all types of PIs at once, regardless of
their binding site or mechanism of action. The third dis-
tinctive advantage of a cell-based system over structure-
based designs is that a cell-based system can eliminate any
compounds that have strong cytotoxic effect. Most im-
portantly, a simple, economical, and easy-to-maintained
cellular system will allow searching for potential PIs in a
large-scaled HTS system, increasing our chances of suc-
cess. Thus, cell-based drug screening systems may be a
useful alternative strategy that will overcome many of
the inherited shortcomings associated with the
structure-based drug design and identify new PIs thatwould be difficult to develop using structure-based
designs.
There are currently several cell-based PI screening sys-
tems using Escherichia coli (E. coli) [73,74] or human cells
[75-77]. All of these systems are capable of screening for
HIV-1 PR activity and two of them also are capable of
screening for cytotoxicity [74,76]. Cheng et al. developed a
cell-based assay model for PR-induced cytotoxicity by
expressing HIV-1 PR in E. coli [74], an organism that
shows cytotoxicity upon PR expression, just like in mam-
malian cells [78,79]. Fuse et al. expressed HIV-1 PR in a
chimeric protein along with green fluorescence protein in
a novel human kidney cell line (E-PR293) to assay for both
PR levels and cytotoxicity [76]. These systems are useful,
but neither is ideal for cell-based HTS. E. coli is a prokary-
otic organism that is different from a mammalian cell in
many ways, so results obtained from E. coli may not trans-
late well to humans. E-PR293 is a human cell line, which
is expensive and time-consuming to maintain. Hence, the
system developed by Fuse at al. will make a good con-
firmatory assay, but may be too expensive for cell-based
HTS. Therefore, we are still in need of a suitable model
organism for a viable cell-based HTS system.
An ideal model organism for PR studies should: 1) be
easy to maintain and manipulate, 2) share fundamental
cellular features and processes with mammalian cells, and
3) have cellular response to PR similar to cellular effects
of PR in mammalian cells. Fission yeast possesses many of
these properties. Specifically, fission yeast is a unicellular
organism that is very easy to grow and manipulate in the
laboratory. It typically divides every 3–4 hours at 30°C
with active agitation compared to 24 hours for human cell
lines. Despite its simplicity, fission yeast, as a eukaryotic
organism, shares very similar fundamental cellular features
and processes as mammalian cells. For example, it has
similar cell cycles as cells of higher eukaryotes [80,81]. In
addition, fission yeast contains a splicing mechanism that
is able to remove introns from genes of higher eukaryotes
and mammals [81-83]. Since fission yeast is capable of
post-translational modification (e.g., phosphorylation and
acetylation), the heterogeneous proteins produced by fis-
sion yeast are very close to their natural forms in mamma-
lian cells [80,82,83].
Based on the above mentioned properties, a fission yeast
cell-based HTS system may be a feasible alternative for fu-
ture screenings of PIs. Its feasibility is supported by the
fact that fission yeast has been used extensively as a model
system to study HIV-1 viral protein R (Vpr) during HIV-1
infection {reviewed in [84-86]}. For instance, Vpr induces
similar cellular changes in both fission yeast and human
cells [87], which include: 1) cell cycleG2/M arrest
[86,88,89], 2) cytoplasm to nuclear transport of viral pre-
intergration complex [81,89], and 3) induction cell death
and apoptosis [88-90]. Taking advantage of Vpr-induced
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et al. has established a HTS system for screening HIV-1
inhibitors and cellular suppressors. In a pilot study, they
have shown that this cell-based HTS is capable of picking
out a Vpr inhibitor from a chemical drug library [91]. This
HTS system is currently being employed by the National
Institutes of Health Chemical Genomics Center to screen
for Vpr inhibitors.
As for the cellular effects of HIV-1 PR, there is cur-
rently no published data on whether HIV-1 PR behaves
similarly in fission yeast and in mammalian cells. How-
ever, based on our many years’ experience in studying
HIV-1 Vpr in fission yeast cells, we have reason to be-
lieve that fission yeast should be a reasonable model to
study HIV-1 PR as well. Specifically, since expression of
HIV-1 Vpr induces cell death via apoptosis in both fis-
sion yeast and mammalian cells [86-90], it is likely that
expression of HIV-1 PR, which also causes cell death
and apoptosis in mammalian cells, may have a similar
effects in fission yeast and mammalian cells. Blanco
et al. showed that expression of HIV-1 PR in budding
yeast (Saccharomyces cerevisiae) causes cell death [36],
further supporting the idea that HIV-1 PR expression
should have a similar effect in fission yeast.
It should be mentioned that although fission yeast
may serve as a reasonably good model organism for
HTS of PIs, it certainly has its own limitations. For ex-
ample, fission yeast cells have cell walls but human cells
do not, which may limit input of large molecule into the
cell. In addition, fission yeast cells only have 3 chromo-
somes while human cells have 23 pairs. Hence, while
results obtained from studying PR and PI in fission yeast
are more translatable to humans than many organisms
such as E. coli, confirmatory test in human cell system
are still needed to validate their clinical efficacy.
Our current and future effort will focus on the study-
ing and characterization of HIV-1 PR in fission yeast
and to further explore its utility as a HTS system to
search for new PIs.
Conclusion
In this review, we have shown that HIV-1 PR cleaves viral
proteins as well as host cell proteins. The cleavage of host
cell proteins results in cell death via several necrotic and
apoptotic pathways, possibly leading to depletion of CD4+
T-cells. Thus, PIs are particularly useful as ARVs not only
because they inhibit viral replication but also because they
rescue host immune cells. One of the downsides of
current PIs is the rapid emergence of drug resistance due
in part to the fact that all current PIs were designed
against the same site on HIV-1 PR: the enzymatic site. To
combat drug resistance and avoid multi-drug resistance,
allosteric PIs are needed. There are currently several
promising allosteric PI candidates. However, developmentof those drugs has been slow because of the inherited lim-
itations of their structure-based design. Alternatively, cell-
based drug screening system could potentially be a good
alternative approach that is not limited by the systematic
shortcomings of the structure-based design. However, the
current challenge associated with using a cell-based sys-
tem is that there is no suitable model organism to carry
out this assay in an economically feasible way. Fission
yeast might be a good alternative because it is a single-cell
eukaryotic organism. Hence, it is easy to maintain and
manipulate in the laboratory, amendable for large-scale
HTS, and most importantly, it shares many fundamental
cellular features and processes with mammalian cells.
Thus we propose that future efforts should focus on
studying and characterizing HIV-1 PR in fission yeast and
further exploring its potential application as a HTS system
for new PIs.
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